Market Whales and Their Recent Bets on Edwards Lifesciences Options
Express News | Barclays Maintains Overweight on Edwards Lifesciences, Lowers Price Target to $90
Express News | Edward Lifesciences Shares Are Trading Higher, Slightly Rebounding After Falling When the Company Reported Mixed Q3 Results and Issued Weak Guidance This Week. Additionally, Goldman Sachs Maintained a Buy Rating on the Stock
Edwards Lifesciences Is Maintained at Buy by Goldman Sachs
Edwards Lifesciences Price Target Cut to $91.00/Share From $107.00 by Goldman Sachs
Edwards Lifesciences Analyst Ratings
Daily short sale tracking: Avantor's short volume increased by 41 million, with a short sale ratio of 41%
More Unpleasant Surprises Could Be In Store For Edwards Lifesciences Corporation's (NYSE:EW) Shares After Tumbling 34%
Express News | Edwards Lifesciences Corp : Bernstein Cuts Target Price to $65 From $73
Barclays Maintains Edwards Lifesciences(EW.US) With Buy Rating, Cuts Target Price to $90
Barclays Keeps Their Buy Rating on Edwards Lifesciences (EW)
S&P 500, Nasdaq Settle Lower As Tech Stocks Continue To Falter: Greed Index In 'Fear' Zone
Correction: Peijia Medical Unit to Sell Minority Stake in US-Based Medical Device Firm
JenaValve, a partner of Perk Jia Medical, has been fully acquired by Edwards Lifesciences, marking a new chapter in the treatment of aortic valve regurgitation through catheterization.
Suzhou, July 26, 2024 / PRNewswire / -- On July 24, 2024, Peijia Medical (9996.HK) partner JenaValve Technology, Inc. (hereinafter referred to as JenaValve) announced an agreement with the US medical equipment giant Edwards Lifesciences (NYSE: EW, hereinafter referred to as "Edwards") for Edwards Lifesciences to acquire JenaValve wholly. After the transaction, Peijia Medical will continue to exclusively hold the JenaValve Trilogy THV system in the Greater China region.
Hold Rating on Edwards Lifesciences Amid TAVR Challenges and Competitive Pressures
After Edwards Lifesciences (EW.US) unexpectedly lowered its TAVR expectations, both Morgan Stanley and Truist significantly reduced their target stock prices.
In the performance outlook section, the company expects the growth of transcatheter aortic valve replacement (TAVR) products in 2024 to be lower than previously announced expectations. Subsequently, the company's stock price suffered a heavy blow as pessimistic expectations led investors to sell off the stock.
Peijia Medical-B (09996.HK): Edwards Lifesciences plans to acquire JenaValve through a merger.
On July 26th, Guolong News reported that Peijia Medical-B (09996.HK) announced that its wholly-owned subsidiary, Marvel Finder Limited, holds about 1.91% (calculated on a fully diluted and conversion basis) of JenaValve's minority equity, which is recorded in the company's comprehensive financial statements as a financial asset measured at fair value. JenaValve has notified the company that on July 23, 2024 (US time), Edwards Lifesciences (through its wholly-owned subsidiary) agreed to acquire the shares.
Heard on the Street Recap: Detroit Blues -- WSJ
Edwards Lifesciences (NYSE:EW) Plunges 31% After J.P. Morgan and Truist Downgrades
Top 20 U.S. stock trading volume on July 25th: Ford dropped sharply by 18.4%, averaging a loss of 0.3 million per electric vehicle.
On Thursday, Nvidia, the top trading company in the US, fell by 1.72%, marking its third consecutive day of decline with a turnover of 51.53 billion US dollars. Nvidia's partner SMC is reportedly raising 0.95 billion US dollars to stimulate business development with the help of AI server trends. Tesla, ranked second, rose 1.97% with a turnover of 22.201 billion US dollars. UBS Group believes that the profit return of Tesla's AI project is still far away, but the market has given it overly high expectations for its development potential, leading to its stock price far above its reasonable valuation. The bank reaffirmed its "sell" rating on Tesla. Tesla CEO Musk said on Tuesday that Tesla's value lies mainly in its autonomous driving.